AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's i-body technology platform and pipeline of i-bodies; including its lead candidate for treating fibrotic diseases, in particular Idiopathic Pulmonary Fibrosis, AD-214.
A phase I human study is expected to begin in January 2020.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
AdAlta Ltd (ASX:1AD) chief executive officer Sam Cobb updates Proactive Investors on the health-focused company's recent $5 million raising to progress the development of its key AD-214 drug for the treatment of idiopathic pulmonary fibrosis. Cobb says recent animal trials will...
Director Interviews
Full interview: Northern Minerals in strategic discussions with...
